Skip to main content
Top
Published in: International Journal of Hematology 5/2015

01-05-2015 | Case Report

Microcytic anemia in a pregnant woman: beyond iron deficiency

Authors: Noelia Rollón, María Cristina Fernández-Jiménez, María Isabel Moreno-Carralero, María José Murga-Fernández, María Josefa Morán-Jiménez

Published in: International Journal of Hematology | Issue 5/2015

Login to get access

Abstract

Sideroblastic anemias are a heterogeneous group of disorders characterized by anemia of varying severity and the presence of ringed sideroblasts in bone marrow. The most common form of inherited sideroblastic anemia is X-linked sideroblastic anemia (XLSA). In many XLSA patients, anemia responds variably to supplementation with pyridoxine (vitamin B6). We describe the case of a pregnant female with XLSA who had a novel mutation on the ALAS2 gene (c.1218G > T, p.Leu406Phe). Oral chelation therapy was contraindicated and high-dose vitamin B6 would have possible side effects in pregnancy. Serum hepcidin level was very low, indicating increased absorption of iron secondary to ineffective erythropoiesis. Therapy was begun with a low dose of pyridoxine that was increased post-partum. The patient’s liver showed moderate iron deposits. During a subsequent 3-month period of pyridoxine supplementation, serum ferritin level and transferrin saturation decreased, hemoglobin content and serum hepcidin level normalized, and morphologic red cell abnormalities improved markedly. The patient responded well to treatment, showing the pyridoxine responsiveness of this novel ALAS2 mutation. The baby girl had the same mutation heterozygously, and although she was neither anemic nor showed abnormalities in a peripheral blood smear, she had a mild increment in RDW and her condition is now being followed.
Literature
1.
go back to reference Cuijpers ML, Raymakers RA, Mackenzie MA, de Witte TJ, Swinkels DW. Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome. Br J Haematol. 2010;149:322–33.CrossRefPubMed Cuijpers ML, Raymakers RA, Mackenzie MA, de Witte TJ, Swinkels DW. Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome. Br J Haematol. 2010;149:322–33.CrossRefPubMed
2.
go back to reference Ohba R, Furuyama K, Yoshida K, et al. Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS). Ann Hematol. 2013;92:1–9.CrossRefPubMedCentralPubMed Ohba R, Furuyama K, Yoshida K, et al. Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS). Ann Hematol. 2013;92:1–9.CrossRefPubMedCentralPubMed
3.
go back to reference Camaschella C. Recent advances in the understanding of inherited sideroblastic anaemia. Br J Haematol. 2008;143:27–38.CrossRefPubMed Camaschella C. Recent advances in the understanding of inherited sideroblastic anaemia. Br J Haematol. 2008;143:27–38.CrossRefPubMed
4.
go back to reference Cotter PD, Baumann M, Bishop DF. Enzymatic defect in “X-linked” sideroblastic anemia: molecular evidence for erythroid delta-aminolevulinate synthase deficiency. Proc Natl Acad Sci USA. 1992;89:4028–32.CrossRefPubMedCentralPubMed Cotter PD, Baumann M, Bishop DF. Enzymatic defect in “X-linked” sideroblastic anemia: molecular evidence for erythroid delta-aminolevulinate synthase deficiency. Proc Natl Acad Sci USA. 1992;89:4028–32.CrossRefPubMedCentralPubMed
5.
go back to reference Hunter GA, Ferreira GC. 5-aminolevulinate synthase: catalysis of the first step of heme biosynthesis. Cell Mol Biol. 2009;55:102–10.PubMedCentralPubMed Hunter GA, Ferreira GC. 5-aminolevulinate synthase: catalysis of the first step of heme biosynthesis. Cell Mol Biol. 2009;55:102–10.PubMedCentralPubMed
6.
go back to reference Bekri S, May A, Cotter PD, et al. A promoter mutation in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causes X-linked sideroblastic anemia. Blood. 2003;102:698–704.CrossRefPubMed Bekri S, May A, Cotter PD, et al. A promoter mutation in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causes X-linked sideroblastic anemia. Blood. 2003;102:698–704.CrossRefPubMed
7.
go back to reference Campagna DR, de Bie CI, Schmitz-Abe K, et al. X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA-binding site mutations. Am J Hematol. 2014;89:315–9.CrossRefPubMedCentralPubMed Campagna DR, de Bie CI, Schmitz-Abe K, et al. X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA-binding site mutations. Am J Hematol. 2014;89:315–9.CrossRefPubMedCentralPubMed
8.
9.
go back to reference Kaneko K, Furuyama K, Fujiwara T, et al. Identification of a novel erythroid-specific enhancer for the ALAS2 gene and its loss-of-function mutation which is associated with congenital sideroblastic anemia. Haematologica. 2014;99:252–61.CrossRefPubMedCentralPubMed Kaneko K, Furuyama K, Fujiwara T, et al. Identification of a novel erythroid-specific enhancer for the ALAS2 gene and its loss-of-function mutation which is associated with congenital sideroblastic anemia. Haematologica. 2014;99:252–61.CrossRefPubMedCentralPubMed
10.
go back to reference Camaschella C. Hereditary sideroblastic anemias: pathophysiology, diagnosis, and treatment. Semin Hematol. 2009;46:371–7.CrossRefPubMed Camaschella C. Hereditary sideroblastic anemias: pathophysiology, diagnosis, and treatment. Semin Hematol. 2009;46:371–7.CrossRefPubMed
11.
go back to reference Astner I, Schulze JO, van den Heuvel J, Jahn D, Schubert WD, Heinz DW. Crystal structure of 5-aminolevulinate synthase, the first enzyme of heme biosynthesis, and its link to XLSA in humans. EMBO J. 2005;24:3166–77.CrossRefPubMedCentralPubMed Astner I, Schulze JO, van den Heuvel J, Jahn D, Schubert WD, Heinz DW. Crystal structure of 5-aminolevulinate synthase, the first enzyme of heme biosynthesis, and its link to XLSA in humans. EMBO J. 2005;24:3166–77.CrossRefPubMedCentralPubMed
12.
go back to reference May A, Bishop DF. The molecular biology and pyridoxine responsiveness of X-linked sideroblastic anaemia. Haematologica. 1998;83:56–70.PubMed May A, Bishop DF. The molecular biology and pyridoxine responsiveness of X-linked sideroblastic anaemia. Haematologica. 1998;83:56–70.PubMed
13.
go back to reference Cox TC, Bottomley SS, Wiley JS, Bawden MJ, Matthews CS, May BK. X-linked pyridoxine-responsive sideroblastic anemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase. N Engl J Med. 1994;330:675–9.CrossRefPubMed Cox TC, Bottomley SS, Wiley JS, Bawden MJ, Matthews CS, May BK. X-linked pyridoxine-responsive sideroblastic anemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase. N Engl J Med. 1994;330:675–9.CrossRefPubMed
14.
go back to reference Bergmann AK, Campagna DR, McLoughlin EM, et al. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer. 2010;54:273–8.PubMedCentralPubMed Bergmann AK, Campagna DR, McLoughlin EM, et al. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer. 2010;54:273–8.PubMedCentralPubMed
15.
go back to reference Institute of Medicine (Subcommittees on Nutritional Status and Weight Gain During Pregnancy and Dietary Intake and Nutrient Supplements During Pregnancy, Committee on Nutritional Status During Pregnancy and Lactation, Food and Nutrition Board). Water-soluble vitamins. In: Nutrition During Pregnancy: Part II, Nutrient Supplements. Washington, DC: National Academy Press; 1990. p. 351–61. Institute of Medicine (Subcommittees on Nutritional Status and Weight Gain During Pregnancy and Dietary Intake and Nutrient Supplements During Pregnancy, Committee on Nutritional Status During Pregnancy and Lactation, Food and Nutrition Board). Water-soluble vitamins. In: Nutrition During Pregnancy: Part II, Nutrient Supplements. Washington, DC: National Academy Press; 1990. p. 351–61.
16.
go back to reference Hisano M, Suzuki R, Sago H, Murashima A, Yamaguchi K. Vitamin B6 deficiency and anemia in pregnancy. Eur J Clin Nutr. 2010;64:221–3.CrossRefPubMed Hisano M, Suzuki R, Sago H, Murashima A, Yamaguchi K. Vitamin B6 deficiency and anemia in pregnancy. Eur J Clin Nutr. 2010;64:221–3.CrossRefPubMed
17.
go back to reference Masino SA, Kahle JS. Vitamin B6 therapy during childbearing years: cause for caution? Nutr Neurosci. 2002;5:241–2.CrossRefPubMed Masino SA, Kahle JS. Vitamin B6 therapy during childbearing years: cause for caution? Nutr Neurosci. 2002;5:241–2.CrossRefPubMed
18.
go back to reference Bottomley SS. Sideroblastic anemias. In: Greer JP, Arber DA, Glaber B, et al editors. Wintrobe’s Clinical Hematology. 13 ed. Philadelphia: Lippincott, Williams and Wilkins; 2014. p. 643–61. Bottomley SS. Sideroblastic anemias. In: Greer JP, Arber DA, Glaber B, et al editors. Wintrobe’s Clinical Hematology. 13 ed. Philadelphia: Lippincott, Williams and Wilkins; 2014. p. 643–61.
19.
go back to reference Cotter PD, May A, Fitzsimons EJ, et al. Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts. J Clin Invest. 1995;96:2090–6.CrossRefPubMedCentralPubMed Cotter PD, May A, Fitzsimons EJ, et al. Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts. J Clin Invest. 1995;96:2090–6.CrossRefPubMedCentralPubMed
20.
go back to reference Peto TE, Pippard MJ, Weatherall DJ. Iron overload in mild sideroblastic anaemias. Lancet. 1983;1:375–8.CrossRefPubMed Peto TE, Pippard MJ, Weatherall DJ. Iron overload in mild sideroblastic anaemias. Lancet. 1983;1:375–8.CrossRefPubMed
Metadata
Title
Microcytic anemia in a pregnant woman: beyond iron deficiency
Authors
Noelia Rollón
María Cristina Fernández-Jiménez
María Isabel Moreno-Carralero
María José Murga-Fernández
María Josefa Morán-Jiménez
Publication date
01-05-2015
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2015
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-014-1723-7

Other articles of this Issue 5/2015

International Journal of Hematology 5/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine